Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Human Potential Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Trials. 2024 Jul 3;25(1):443. doi: 10.1186/s13063-024-08247-x.
Women with a history of gestational diabetes mellitus (GDM) are 12-fold more likely to develop type 2 diabetes (T2D) 4-6 years after delivery than women without GDM. Similarly, GDM is associated with the development of common mental disorders (CMDs) (e.g. anxiety and depression). Evidence shows that holistic lifestyle interventions focusing on physical activity (PA), dietary intake, sleep, and mental well-being strategies can prevent T2D and CMDs. This study aims to assess the effectiveness of a holistic lifestyle mobile health intervention (mHealth) with post-GDM women in preventing T2D and CMDs in a community setting in Singapore.
The study consists of a 1-year randomised controlled trial (RCT) with a 3-year follow-up period. Post-GDM women with no current diabetes diagnosis and not planning to become pregnant will be eligible for the study. In addition, participants will complete mental well-being questionnaires (e.g. depression, anxiety, sleep) and their child's socio-emotional and cognitive development. The participants will be randomised to either Group 1 (Intervention) or Group 2 (comparison). The intervention group will receive the "LVL UP App", a smartphone-based, conversational agent-delivered holistic lifestyle intervention focused on three pillars: Move More (PA), Eat Well (Diet), and Stress Less (mental wellbeing). The intervention consists of health literacy and psychoeducational coaching sessions, daily "Life Hacks" (healthy activity suggestions), slow-paced breathing exercises, a step tracker (including brisk steps), a low-burden food diary, and a journaling tool. Women from both groups will be provided with an Oura ring for tracking physical activity, sleep, and heart rate variability (a proxy for stress), and the "HAPPY App", a mHealth app which provides health promotion information about PA, diet, sleep, and mental wellbeing, as well as display body mass index, blood pressure, and results from the oral glucose tolerance tests. Short-term aggregate effects will be assessed at 26/27 weeks (midpoint) and a 1-year visit, followed by a 2, 3, and 4-year follow-up period.
High rates of progression of T2D and CMDs in women with post-GDM suggest an urgent need to promote a healthy lifestyle, including diet, PA, sleep, and mental well-being. Preventive interventions through a holistic, healthy lifestyle may be the solution, considering the inextricable relationship between physical and psychological health. We expect that holistic lifestyle mHealth may effectively support behavioural changes among women with a history of GDM to prevent T2D and CMDs.
The protocol study was approved by the National Healthcare Group in Singapore, Domain Specific Review Board (DSRB) [2023/00178]; June 2023. Recruitment began on October 18, 2023.
ClinicalTrials.gov NCT05949957. The first submission date is June 08, 2023.
患有妊娠糖尿病(GDM)的女性在分娩后 4-6 年内发展为 2 型糖尿病(T2D)的风险是没有 GDM 的女性的 12 倍。同样,GDM 与常见精神障碍(CMD)的发展有关(例如焦虑和抑郁)。有证据表明,专注于身体活动(PA)、饮食摄入、睡眠和心理健康策略的整体生活方式干预可以预防 T2D 和 CMD。本研究旨在评估针对产后 GDM 女性的整体生活方式移动健康干预(mHealth)在新加坡社区环境中预防 T2D 和 CMD 的有效性。
这是一项为期 1 年的随机对照试验(RCT),随访期为 3 年。没有当前糖尿病诊断且不计划怀孕的产后 GDM 女性将有资格参加研究。此外,参与者将完成心理健康问卷(例如抑郁、焦虑、睡眠)和他们孩子的社会情感和认知发展。参与者将被随机分配到第 1 组(干预组)或第 2 组(对照组)。干预组将使用“LVL UP App”,这是一种基于智能手机的、由对话代理提供的整体生活方式干预措施,侧重于三个支柱:多运动(PA)、合理饮食(饮食)和减轻压力(心理健康)。干预措施包括健康素养和心理教育辅导课程、日常“生活技巧”(健康活动建议)、缓慢的呼吸练习、计步器(包括快速步)、低负担的饮食日记和日记工具。两组女性都将获得 Oura 戒指,用于跟踪身体活动、睡眠和心率变异性(压力的代理指标),以及 mHealth 应用程序“HAPPY App”,该应用程序提供关于 PA、饮食、睡眠和心理健康的健康促进信息,以及显示体重指数、血压和口服葡萄糖耐量试验的结果。短期综合效果将在 26/27 周(中点)和 1 年就诊时进行评估,然后在 2、3 和 4 年随访期间进行评估。
产后 GDM 女性 T2D 和 CMD 进展率较高,表明迫切需要促进健康的生活方式,包括饮食、PA、睡眠和心理健康。考虑到身心健康之间不可分割的关系,通过整体、健康的生活方式进行预防干预可能是解决方案。我们预计,整体生活方式 mHealth 可能会有效地支持有 GDM 病史的女性进行行为改变,以预防 T2D 和 CMD。
该方案研究已获得新加坡国家医疗保健集团、特定领域审查委员会(DSRB)的批准[2023/00178];2023 年 6 月。招募于 2023 年 10 月 18 日开始。
ClinicalTrials.gov NCT05949957。首次提交日期为 2023 年 6 月 8 日。